AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings data on Tuesday. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.03), MarketWatch Earnings reports. AngioDynamics had a net margin of 5.10% and a return on equity of 5.85%. The firm had revenue of $86.34 million during the quarter, compared to analyst estimates of $88.30 million. During the same quarter in the previous year, the business posted $0.23 earnings per share. AngioDynamics’s revenue for the quarter was up 3.0% compared to the same quarter last year. AngioDynamics updated its FY 2019 guidance to $0.82-0.86 EPS and its FY19 guidance to $0.82-0.86 EPS.
Shares of NASDAQ:ANGO opened at $23.88 on Tuesday. AngioDynamics has a 12 month low of $17.17 and a 12 month high of $25.48. The company has a current ratio of 2.88, a quick ratio of 1.86 and a debt-to-equity ratio of 0.25. The firm has a market cap of $848.96 million, a P/E ratio of 32.27 and a beta of 0.75.
Several equities research analysts recently commented on ANGO shares. Canaccord Genuity lifted their price target on shares of AngioDynamics from $20.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, January 7th. BidaskClub lowered shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 6th. Finally, Zacks Investment Research lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $21.11.
COPYRIGHT VIOLATION WARNING: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://sportsperspectives.com/2019/04/02/angiodynamics-ango-releases-earnings-results-misses-expectations-by-0-03-eps.html.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.